NMTC NEUROONE MEDICAL TECHNOLOGIES Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1500198 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.8%
TTM net income YoY-39.5%
TTM EPS YoY-20.9%
Revenue 3-yr CAGR94.9%
Net income 3-yr CAGR—
Margins
Gross margin55.6%
Operating margin-83.4%
Net margin-78.6%
FCF margin-75.6%
EBITDA margin-81.0%
Returns
ROE-124.7%
ROA-87.6%
ROIC (approx.)-671.9%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.97M | $1.86M | $2.89M | $2.74M | $1.70M | $1.39M | $3.27M | $272,284 |
| Cost of revenue | $790,496 | $871,786 | $1.32M | $1.21M | $781,215 | $615,489 | $1.35M | $131,222 |
| Gross profit | $1.18M | $990,264 | $1.57M | $1.53M | $914,835 | $771,061 | $1.93M | $141,062 |
| R&D expense | $1.43M | $1.47M | $1.39M | $1.12M | $1.18M | $1.51M | $1.17M | $1.11M |
| SG&A expense | $2.18M | $1.92M | $1.89M | $1.78M | $1.62M | $1.94M | $2.04M | $1.84M |
| Operating income | -$2.42M | -$2.40M | -$1.71M | -$1.37M | -$1.89M | -$2.68M | $1.71M | -$2.82M |
| Pretax income | -$2.01M | -$2.38M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | $1.79M | -$3.35M |
| Net income | -$2.01M | -$2.38M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | $1.79M | -$3.35M |
| EBITDA | -$2.38M | -$2.34M | -$1.64M | -$1.31M | -$1.83M | -$2.62M | $1.78M | -$2.75M |
| EPS (basic) | -0.23 | -0.28 | -0.03 | — | -0.19 | -0.44 | 0.06 | — |
| EPS (diluted) | -0.28 | -0.28 | -0.03 | — | -0.19 | -0.44 | 0.06 | — |
| Weighted avg. shares (diluted) | 8.74M | 8.48M | 50.33M | — | 8.10M | 5.19M | 30.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.05M | $2.80M | $3.56M | $6.57M | $8.04M | $1.32M | $1.13M | $1.46M |
| Receivables | $1.10M | $1.90M | $2.66M | $1.26M | — | $318,780 | $2.37M | $176,636 |
| Inventory | $2.29M | $2.10M | $1.67M | $2.23M | $1.90M | $1.83M | $1.93M | $2.64M |
| Current assets | $5.79M | $7.11M | $8.07M | $10.23M | $10.17M | $3.75M | $5.71M | $4.63M |
| PP&E, net | $202,333 | $230,596 | $244,906 | $259,222 | $314,588 | $334,853 | $381,711 | $416,843 |
| Intangibles | $28,210 | $33,789 | $39,368 | $44,946 | $50,525 | $56,104 | $61,683 | $67,262 |
| Total assets | $6.19M | $7.57M | $8.58M | $10.79M | $10.82M | $4.46M | $6.49M | $5.37M |
| Current liabilities | $2.04M | $1.69M | $1.26M | $2.30M | $1.43M | $1.76M | $1.57M | $2.21M |
| Total liabilities | $2.42M | $2.49M | $2.18M | $3.71M | $2.64M | $3.33M | $3.56M | $4.55M |
| Shareholders' equity | $3.77M | $5.08M | $6.40M | $7.07M | $8.18M | $1.13M | $2.94M | $822,013 |
| Shares outstanding | 8.70M | 8.62M | 50.41M | 8.33M | 49.82M | 31.39M | 30.84M | 30.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.08M | -$1.33M | -$3.12M | -$1.53M | -$1.46M | -$56,144 | $208,049 | -$2.67M |
| Capital expenditure | $19,659 | $38,516 | $40,754 | $10,607 | $43,548 | $3,171 | $24,416 | $36,905 |
| Free cash flow | -$1.10M | -$1.37M | -$3.16M | -$1.54M | -$1.51M | -$59,315 | $183,633 | -$2.70M |
| Investing cash flow | -$19,659 | -$38,516 | -$40,754 | -$10,607 | -$43,548 | -$3,171 | -$24,416 | -$36,905 |
| Financing cash flow | $345,033 | $609,622 | $147,823 | $66,978 | $8.23M | $245,216 | -$509,325 | $2.54M |
| Depreciation & amortization | $41,423 | $54,450 | $65,523 | $64,324 | $61,015 | $60,055 | $65,127 | $64,127 |
| Stock-based compensation | $352,777 | $342,135 | $359,255 | $358,560 | $316,654 | $250,170 | $339,224 | $340,371 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.